Zobrazeno 1 - 4
of 4
pro vyhledávání: '"33"'
Autor:
Hiroyuki Abe, Tsuyoshi Mori, Kaori Tomida, Hirotomi Cho, N Itoi, Yoshihiro Kubota, Yuki Kawai, Tohru Tani, Tomoko Umeda
Publikováno v:
Cancer Research. 72:P1-15
Background: Although taxanes have become a key chemotherapeutic drug in breast cancer treatment. Taxanes inhibit the growth of cancer cells by disrupting the functioning of their microtubules; however, the microtubules of nerve cells are also affecte
Autor:
L van Warmerdam, C. Fontaine, A Vos, E de Jongh, Frans L. G. Erdkamp, D van Brummelen, C. Dopchie, J Janssens
Publikováno v:
Cancer Research. 70:P6-11
Introduction: Current treatment recommendations provide limited guidance for chemotherapy (CT) of MBC, while physicians have many options to choose from. We undertook a retrospective survey to describe and compare actual CT approaches to MBC in clini
Autor:
David Coeffic, Dominique Dramais, Thomas Bachelot, Jocelyne Provencal, Agathe Bajard, Jean-Paul Guastalla, Isabelle Ray-Coquard, R. Ferri-Dessens, David Pérol
Publikováno v:
Cancer Research. 69:2099-2099
Background: Docetaxel plus capecitabine (DC) combination therapy improves both time to disease progression and overall survival over docetaxel alone in metastatic breast cancer (MBC). The aim of the ERASME-4 trials was to assess the efficacy of DC vs
Autor:
R. C. Hermann, Toncred M. Styblo, D Hicklin, K Carlson, Jayanthi Srinivasiah, Harvey L. Bumpers, N Sellers, Seema Harichand-Herdt, F. M. Schnell, Ruth O'Regan, Monica Rizzo, Amelia Zelnak, Carl J. D'Orsi, Sheryl G. A. Gabram, T Pierce, D Senior-Crosby
Publikováno v:
Cancer Research. 69:5122
Abstract #5122 Background The efficacy of D and C as single agents and in combination is well established in the treatment of metastatic breast cancer. Novel sequential and concurrent regimens of D and C were evaluated in patients with her2-negative